

Antithrombin activity of the hirudin N-terminal core domain residues 1–43

Jui-Yoa Chang, Jean-Marc Schlaeppli and Stuart R. Stone*

Pharmaceuticals Research Laboratories, Ciba-Geigy Ltd., and *Friedrich Mieschler Institute,
CH-4002 Basel, Switzerland

Received 26 October 1989

Hirudin N-terminal core domain residues 1–43 (*r*-Hir^{1–43}) were prepared from limited proteolysis of recombinant hirudin by *V8 Staphylococcal* protease followed by purification with reversed-phase HPLC. *r*-Hir^{1–43} lacks the putative reactive site of hirudin (Lys⁴⁷), but binds to thrombin (with *K_i* of 300 nM) and blocks the catalytic activity of the protease. The structural element which accounts for the thrombin inhibitory activity of *r*-Hir^{1–43} is analyzed in this report.

Hirudin; Hirudin fragment; Hirudin-thrombin interaction

1. INTRODUCTION

Hirudin is the most potent thrombin-specific inhibitor known [1,2]. This inhibitor was first isolated from the leech *Hirudo medicinalis* [3] and can be now produced by recombinant DNA technology [4,5]. The exceedingly high binding affinity and specificity of the hirudin-thrombin complex has evoked intense interest in elucidating their interaction at the molecular level. Two domains of hirudin have been identified to bind specifically to independent sites of thrombin. The acidic C-terminal domain (residues 52–65) has been predicted [6] and proven [7,8] to bind to a non-catalytic site of thrombin which is required for fibrinogen recognition [9,10]. Seven lysyl residues of thrombin were recently identified to participate in this recognition site [11,12].

The N-terminal domain (*r*-Hir^{1–52}) blocks the active site of thrombin [13]. Within the N-terminal domain, there are three lysines (Lys²⁷, Lys³⁶ and Lys⁴⁷), and Lys⁴⁷ was thought to be the reactive site [2,6]. Site-directed mutagenesis subsequently confirmed a role for Lys⁴⁷, but at the same time also demonstrated that its contribution to the overall hirudin-thrombin binding was marginal. Replacement of Lys⁴⁷ by either Gln [14], Glu [15] or Asn [16] caused only a ten-fold increase of the dissociation constant. Indeed the more important structural constituent of hirudin which blocks the active site region of thrombin appears to be a hydrophobic segment which is complementary to an apolar binding pocket adjacent to the catalytic center of thrombin [10,17–19]. Although the region encompassing residues

40–48 was suggested to play a role, the composition and exact location of this hydrophobic region is not known. In this communication, we demonstrate that part of this hydrophobic segment is located within the fragment containing residues 1–43 (*r*-Hir^{1–43}).

2. EXPERIMENTAL

2.1. Materials

Human alpha-thrombin was purchased from the Center for Diagnostic Products (Boston, USA). Recombinant desulfated hirudin (CGP-39393) has been produced by Ciba-Geigy in collaboration with Platorgan KG (Bad Zwischenahn, FRG) [4] and was kindly provided by Dr W. Maerki. *N*-α-Acetylated-Hir^{43–52} (CGP 48389) was kindly supplied by Dr H. Rink. *Staphylococcus aureus* strain V8 protease was from Sigma. A monoclonal antibody raised against *r*-hirudin (MAb 4049-83-12) was produced and characterized as described in [20]. The substrate tosyl-Gly-Pro-Arg-pNa (Chromozym TH) was from Boehringer Mannheim, FRG.

2.2. Digestion of *r*-hirudin and *r*-Hir^{1–43} by V8 protease

To prepare *r*-Hir^{1–43}, *r*-hirudin (100 µg) was mixed with 30 µg of V8 protease in 50 µl of 50 mM ammonium bicarbonate buffer (pH 8.0, containing 2 mM EDTA). Digestion was carried out at 37°C for 1 h. The proteolytic fragments were separated by reverse-phase HPLC with the conditions described in fig.1. For extensive digestion of *r*-Hir^{1–43} and its oxidized form, the samples were digested with V8 protease under similar conditions up to 24 h (with the exception of an enzyme/substrate weight ratio of 1:10). Aliquots of the time course digested sample were removed, freeze-dried and analyzed by quantitative N-terminal analysis to evaluate the extent of digestion at Glu⁸-Ser⁹ and Glu¹⁷-Gly¹⁸ (fig.2).

2.3. Amino acid analysis and quantitative N-terminal analysis

Amino acid compositions of hirudin fragments were determined by the dimethylaminoazobenzene sulfonyl chloride precolumn derivatization method [21]. N-terminal amino acids of hirudin fragments were quantitatively analyzed by the dimethylaminoazobenzene isothiocyanate (DABITC) method [22].

Correspondence address: J.-Y. Chang, R-1056, 309 Ciba-Geigy Ltd., Basel CH-4002, Switzerland

2.4. Competitive ELISA assay

The two-step competitive ELISA, using 96-well microtiter plates coated with biotinylated *r*-hirudin complexed with avidin was described in [20].

2.5. Amidolytic assay of thrombin

Assays were performed as described previously [23] at 37°C in 0.05 M Tris-HCl buffer, pH 7.8, containing 0.1 M NaCl and 0.1% poly(ethylene glycol), $M_r = 6000$.

3. RESULTS

3.1. Preparation and characterization of *r*Hir¹⁻⁴³

When intact hirudin was digested by V8 protease, Glu-Xaa bonds at the C-terminal region were preferentially cleaved, with Glu⁴³-Gly⁴⁴ being the most susceptible linkage [6]. HPLC separation of the hirudin digest allowed the N-terminal core domain (*r*-Hir¹⁻⁴³) to be isolated with purity over 99% (fig.1). The purity of *r*-




Fig.1. HPLC purification of *r*-Hir¹⁻⁴³. (A) Separation by reverse-phase HPLC of recombinant hirudin fragments obtained after 1 h digestion by V8 protease. The peaks were identified by amino acid analysis. 100 μ g of material was applied to the column. The column was Vydac C-18, 5 μ m, for peptide and protein. Solvent A was 0.1% TFA in water. Solvent B was 0.1% TFA in acetonitrile/water (6:4, v/v). There was a linear gradient from 20% to 80% B in 30 min. The flow rate was 1 ml/min. (B) The peak corresponding to *r*-Hir¹⁻⁴³ was collected (from 25 repetitive injections), pooled and rechromatographed using the same conditions as in (A). 8 μ g of material was applied on the column.

Table 1

Amino acid composition^a of *r*-Hir¹⁻⁴³

Amino acid	Found	Expected
Asp	6.23	(6)
Glu	6.80	(7)
Ser	2.95	(3)
Thr	3.22	(3)
Gly	6.76	(7)
Ala	0.10	(0)
Arg	0.17	(0)
Pro	0.06	(0)
Val ^b	2.70	(4)
Met	0.08	(0)
Ile	0.71	(1)
Leu	3.26	(3)
Phe	0.08	(0)
1/2 Cys ^c	5.90	(6)
Lys	2.10	(2)
His	0.13	(0)
Tyr	1.04	(1)

^a 1 μ g of the sample was hydrolyzed by gas-phase 6 N HCl, dabsylated and 50 ng of the derivatized sample was analyzed

^b The lower than expected value of Val is due to incomplete digestion of Val-Val

^c Quantitatively evaluated as cystine (2.95 residues/mol)

Hir¹⁻⁴³ was further confirmed by quantitative N-terminal analysis (Val, >99%) and amino acid analysis (table 1).

r-Hir¹⁻⁴³ retains the compact structure due to the intactness of the three disulfide bonds. While denatured and oxidized *r*-Hir¹⁻⁴³ was readily digested by V8 protease at Glu⁸-Ser⁹ and Glu¹⁷-Gly¹⁸, its intact form was hardly digestible even after prolonged incubation (fig.2). In an ELISA assay, we have employed a monoclonal antibody to examine the cross reactivity of




Fig.2. The digestion rate of two Glu-Xaa bonds of *r*-Hir¹⁻⁴³ by V8 protease. The intact *r*-Hir¹⁻⁴³ (dashed lines) and performic acid-oxidized *r*-Hir¹⁻⁴³ (solid lines) were digested by V8 protease under identical conditions (see text). The digestion rate of Glu⁸-Ser⁹ and Glu¹⁷-Gly¹⁸ was evaluated by quantitative N-terminal analysis. The recovery of the N-terminal Val was taken as 100%.




Fig. 3. Competitive ELISA. Assay of MAb 4049-83-12 binding to intact recombinant hirudin (\triangle), $r\text{-Hir}^{1-52}$ (\blacktriangle), $r\text{-Hir}^{1-43}$ (\circ) and $N\text{-}\alpha$ -acetyl-Hir $^{43-52}$ (\bullet). $B/B_0 \times 100\%$ represents the percentage of MAb bound to the plate.

intact r -hirudin, $r\text{-Hir}^{1-52}$, $r\text{-Hir}^{1-43}$ and $N\text{-}\alpha$ -acetylated-Hir $^{43-52}$. This antibody (MAb4049-83-12) recognizes the epitope of r -hirudin at the region encompassing residues Glu 43 to Lys 47 [20]. The results are shown in fig. 3. r -Hirudin and $r\text{-Hir}^{1-52}$ exhibit over 95% cross-reactivity. The antibody, however, does not bind to either $r\text{-Hir}^{1-43}$ or Hir $^{43-52}$. The latter result indicates that the conformation of the segment residues 43–52 within $r\text{-Hir}^{1-52}$ cannot be mimicked by synthetic peptide. This result is inconsistent with the finding that $N\text{-}\alpha$ -acetylated-Hir $^{43-52}$ did not display appreciable thrombin inhibitory activity even at the low micromolar concentration (data not shown).

3.2. The thrombin inhibitory activity of $r\text{-Hir}^{1-43}$

Initial velocity experiments in which both the substrate and $r\text{-Hir}^{1-43}$ were varied established that $r\text{-Hir}^{1-43}$ was a competitive inhibitor of thrombin (fig. 4). These data were fitted by weighted linear regression [24] to the equation describing competitive inhibition [25] to




Fig. 4. Effect of $r\text{-Hir}^{1-43}$ on the amidolytic activity of alpha-thrombin. Assays were performed as described in section 2 with the tosyl-Gly-Pro-Arg-pNa in the presence of 0 (\diamond), 225 (Δ), 450 (∇) and 900 (\square) nM of $r\text{-Hir}^{1-43}$. The lines represent the best fit of the data to the equation for competitive inhibition; the estimates obtained from the analysis of the data were: $K_{cat} = 251 \pm 5 \text{ s}^{-1}$, $K_m = 9.1 \pm 0.4 \mu\text{M}$ and $K_i = 299 \pm 12 \text{ nM}$.

yield an estimate of $299 \pm 12 \text{ nM}$ for the inhibition constant (K_i). This value corresponds to a binding energy of 38.7 kJ mol^{-1} .

4. DISCUSSION

We have demonstrated that the N-terminal core domain of hirudin ($r\text{-Hir}^{1-43}$) devoid of the putative reactive site still possesses thrombin inhibitory activity. $r\text{-Hir}^{1-43}$ contains two lysyl residues (Lys 27 and Lys 36), however, it is unlikely that these two lysines would contribute to its interaction with thrombin. Lys 27 and Lys 36 are not conserved in about 14 hirudin variants which have been sequenced so far (for review, see [26]). Replacement of them by either Gln [14], Glu or Ile [15] caused no effect on the hirudin-thrombin binding affinity. Thus, the structural element of $r\text{-Hir}^{1-43}$ which blocks the active site region of thrombin is most likely a hydrophobic cluster which is complementary to an apolar binding pocket of thrombin [10,18,19]. This apolar binding pocket is immediately adjacent to the catalytic center of thrombin [10] and makes a significant contribution towards thrombin's specificity for fibrinogen, tripeptide substrates (e.g. chromozym TH) and many nonfibrinogen polypeptide substrates [18]. The specificity of thrombin for fibrinogen is further enhanced by an independent fibrinogen recognition site of the enzyme. At least 7 lysyl residues within the B-chain of thrombin (Lys 21 , Lys 52 , Lys 65 , Lys 77 , Lys 106 , Lys 107 and Lys 154) have been identified to be involved in this fibrinogen recognition site [11,12].

As compared to $r\text{-Hir}^{1-52}$ [13], $r\text{-Hir}^{1-43}$ has a 12-fold increased dissociation constant with thrombin. This suggests that residues 43–52 contain some structural elements that interact with the active site region of thrombin. This is further supported by the observation that the monoclonal antibody (MAb 4049-83-12) which binds to this domain completely neutralizes the anticoagulant activity of hirudin [20]. Synthetic peptide Ac-Gly-Thr-Pro-Lys-Pro-CONH $_2$ (corresponding to residues 44–48 of hirudin) was also found to be a




Fig. 5. Structure and functional domain of recombinant hirudin. $r\text{-Hir}^{1-43}$ and $r\text{-Hir}^{43-52}$ contain structural elements which bind to the active site region of thrombin. The structural elements which bind to the active site region of thrombin are exclusively located with $r\text{-Hir}^{1-52}$. The structural elements which bind to the fibrinogen recognition site of thrombin are exclusively located within $r\text{-Hir}^{52-65}$. The three disulfide linkages (\bullet — \bullet) and three lysyl residues (\blacksquare) are denoted.

moderate reversible inhibitor of thrombin with a K_i of 120 μ M [29]. In addition to Lys⁴⁷ as the putative reactive site, Pro⁴⁶ and Pro⁴⁸ may also form part of this hydrophobic cluster. In the structure of hirudin elucidated by NMR [27,28], Pro⁴⁶ and Pro⁴⁸ are close to Val¹, Val² and Tyr³ [27]. Chemical modification of the N-terminal Val was quantitatively protected upon complexing with thrombin [11]. Substitution of Val¹ and Val² for amino acids other than hydrophobic residues caused a marked increase of the hirudin-thrombin dissociation constant [30]. Based on these data, it seems possible that Val¹, Val², Tyr³, Pro⁴⁶ and Pro⁴⁸ are major constituents of a discontinuous hydrophobic site in hirudin that accounts for the binding strength of *r*-Hir¹⁻⁴³ and *r*-Hir¹⁻⁵² with thrombin. The domains of hirudin which have been identified to contribute to the hirudin-thrombin complex are summarized in fig.5.

Acknowledgements: The authors thank Dr. W. Maerki and Dr. H. Rink for supplying recombinant hirudin and synthetic hirudin fragment residues 43-52.

REFERENCES

- [1] Markwardt, F. (1970) *Methods Enzymol.* 19, 924-932.
- [2] Bagdy, D., Barabas, E., Graf, L., Petersen, T.E. and Magnusson, S. (1976) *Methods Enzymol.* 45, 669-678.
- [3] Markwardt, F. and Walsmann, P. (1958) *Hoppe-Seyler's Z. Physiol. Chem.* 312, 85-98.
- [4] Meyhack, B., Heim, J., Rink, H., Zimmermann, W. and Maerki, W. (1987) *Thromb. Res.*, suppl. VII, 33.
- [5] Harvey, R.P., Degryse, E., Stefani, L., Schamber, F., Cazenave, J.-P., Courtney, M., Tolstoshev, P. and Lecocq, J.-P. (1986) *Proc. Natl. Acad. Sci. USA* 83, 1084-1088.
- [6] Chang, J.-Y. (1983) *FEBS Lett.* 164, 307-313.
- [7] Mao, S.J.T., Yates, M.T., Owen, T.J. and Krstenansky, J.L. (1988) *Biochemistry* 27, 8170-8173.
- [8] Maraganore, J.M., Chao, B., Joseph, M.L., Jablonski, J. and Ramachandran, K.L. (1989) *J. Biol. Chem.* 264, 8692-8698.
- [9] Magnusson, S. (1971) in: *The Enzyme*, vol. 3 (Boyer, P.D. ed.) pp. 277-321, Academic Press, New York.
- [10] Fenton, J.W. (1981) *Ann. N.Y. Acad. Sci.* 370, 468-495.
- [11] Chang, J.-Y. (1989) *J. Biol. Chem.* 264, 7141-7146.
- [12] Chang, J.-Y., Ngai, P.K., Rink, H., Dennis, S. and Schlaeppli, J.-M., submitted.
- [13] Dennis, S., Wallace, A., Hofsteenge, J. and Stone, S.R. (1989) *Eur. J. Biochem.*, in press.
- [14] Braun, P.J., Dennis, S., Hofsteenge, J. and Stone, S.R. (1988) *Biochemistry* 27, 7517-7522.
- [15] Dodt, J., Koehler, S. and Baici, A. (1988) *FEBS Lett.* 229, 87-90.
- [16] Degryse, E., Acker, M., Defreyn, G., Bernat, A., Maffrand, J.P., Roitsch, C. and Courtney, M. (1989) *Protein Eng.* 2, 459-465.
- [17] Fenton, J.W. and Bing, D. (1986) *Semin. Thromb. Hemost.* 12, 200-208.
- [18] Chang, J.-Y. (1985) *Eur. J. Biochem.* 151, 217-224.
- [19] Berliner, L.J. (1984) *Mol. Cell. Biochem.* 61, 159-172.
- [20] Schlaeppli, J.-M., Vekemans, S., Rink, H. and Chang, J.-Y., submitted.
- [21] Knecht, R. and Chang, J.-Y. (1986) *Anal. Chem.* 58, 2375-2379.
- [22] Chang, J.-Y. (1988) *Anal. Biochem.* 170, 542-556.
- [23] Hofsteenge, J., Taguchi, H. and Stone, S.R. (1986) *Biochem. J.* 237, 243-251.
- [24] Cornish-Bowden, A. and Endrenyi, L. (1981) *Biochem. J.* 193, 1005-1008.
- [25] Fromm, H.J. (1975) *Enzyme Kinetics*, Springer, Berlin.
- [26] Steiner, V. (1988) *Diplom thesis*, University of Basel, Switzerland.
- [27] Folkers, P.J.M., Clore, G.M., Driscoll, P.C., Dodt, J., Koehler, S. and Gronenborn, A.M. (1989) *Biochemistry* 28, 2601-2617.
- [28] Haruyama, H. and Wuethrich, K. (1989) *Biochemistry* 28, 4301-4312.
- [29] Bailie, J.R. and Walker, B. (1989) *Biochem. Soc. Trans.* 17, 692-693.
- [30] Wallace, A., Dennis, S., Hofsteenge, J. and Stone, S.R., *Biochemistry*, in press.